Treatment with rituximab — commonly used off-label for cold agglutinin disease (CAD) — was reported to successfully resolve a serious case of CAD secondary to an Epstein-Barr virus (EBV) infection and potential contraceptive pill toxicity in a young woman in Europe. The woman had developed severe jaundice and liver…
News
Establishing a diagnosis of autoimmune hemolytic anemia (AIHA), a group of conditions including cold agglutinin disease (CAD), is sometimes difficult, due to the high variability in signs and symptoms and the possibility of a secondary cause, a review study showed. “Additionally, therapy is poorly evidence-based and mainly funded on…
Zydus Lifesciences’ desidustat eases the anemia and red blood cell destruction that mark autoimmune hemolytic anemia, or AIHA, a group of autoimmune conditions that includes cold agglutinin disease (CAD), a study in a mouse model has found. The oral therapy was shown to stimulate red blood cell production…
Parsaclisib, an experimental oral therapy from Incyte, safely and effectively increased levels of hemoglobin in about half of people with cold agglutinin disease (CAD) in a small Phase 2 clinical trial, a study shows. Data from the study (NCT03538041), which included people with other forms of autoimmune…
Restarting Enjaymo (sutimlimab) after stopping it for up to four months was generally safe and brought blood markers of cold agglutinin disease (CAD) back to levels before its cessation. These are the findings of a Japanese open-label extension (OLE) study wherein seven CAD patients who completed one of…
Recordati agreed to acquire the global rights to Enjaymo (sutimlimab), the only approved targeted therapy for cold agglutinin disease (CAD), from Sanofi. “With a strong clinical profile and as the only product approved for the treatment of CAD, Enjaymo addresses a serious unmet medical need for patients…
Researchers have developed an artificial intelligence (AI)-based model designed to identify existing medicines that could be repurposed to treat rare conditions such as cold agglutinin disease (CAD). The model, called TxGNN, was able to identify possible therapeutic candidates for more than 17,000 conditions in a study, and researchers believe…
How childhood autoimmune hemolytic anemia (AIHA) — a group of rare conditions that includes cold agglutinin disease (CAD) — is defined and classified varies widely, as does the approach to care for children with hard-to-treat disease, a review study shows. “Standardized definitions and classifications are needed to guide collaborative efforts…
The detection of cold agglutinins, the self-reactive antibodies that drive cold agglutinin disease (CAD), was crucial for the correct diagnosis and management of anemia — lower than normal levels of red blood cells or hemoglobin — in a 37-year-old man with several traumatic injuries after a motorcycle accident, according…
In a young girl in India, cold agglutinin disease (CAD) secondary to a respiratory infection resulted in symptoms suggestive of vasculitis, a group of conditions marked by blood vessel inflammation, a study reported. The symptoms mimicking vasculitis included blueish-blackish discoloration of the nose’s tip that indicated tissue cell death…
Recent Posts
- The life lessons I learned from frigid Friday night football games
- CAD study highlights need for more sensitive bone marrow testing
- Five things I do to have a positive patient experience
- Real-world data show Enjaymo reduces blood cell loss in CAD
- Diagnosis of primary CAD difficult with standard criteria: Study
- A crack emerges, leading to more CAD care for this antique
- Attending church can be challenging for this CAD patient
- Cell therapy helps woman with rare combination of 3 diseases
- National ‘That Sucks’ Day reminds me of all this weary CAD warrior endures
- Chemotherapy triggers cold agglutinin disease in woman with breast cancer